gastric cancer May 12, 2022 ALK Inhibitors Show Benefit in Subset of GI Cancers, Strengthening Tissue-Agnostic Potential Premium May 9, 2022 Theseus Pharmaceuticals Addressing KIT, EGFR Resistance With Pan-Variant Inhibitors Premium Apr 29, 2022 Merck Nabs European Approvals for Keytruda in Cervical Cancer, Biomarker-Defined Solid Tumors Apr 8, 2022 AstraZeneca Licenses Claudin18.2, CD3 Antibody from Harbour BioMed in $350M Deal Mar 29, 2022 Innovent Begins Phase I Trial of IBI389 in Claudin18.2-Expressing Solid Tumors Mar 15, 2022 Imugene Inks Deal With Merck to Study HER-Vaxx, Keytruda in HER2-Positive Gastric Cancer Patients Mar 3, 2022 Carsgen to Start Phase II Trial of CAR T-Cell Therapy for Advanced Gastric, GEJ Cancer in China Mar 2, 2022 Gene Signature Predicts Response to Chemotherapy, Immunotherapy in Gastric Cancer Premium Feb 24, 2022 Gene Expression Biomarker Panel Shows Prognostic, Predictive Promise for Gastric Cancer Premium Jan 31, 2022 Leica Biosystems, Leap Therapeutics Partner to Develop CDx for Anti-DKK1 Cancer Therapy Jan 25, 2022 ITM Isotope Technologies Begins Phase III Radionuclide Study in Patients With GEP-NETs Jan 3, 2022 With New Cancer Theranostics Poised to Enter the Market, Access Disparities Loom Premium Dec 3, 2021 I-Mab Begins Study of Uliledlimab Plus Tecentriq in Advanced Solid Tumors Nov 29, 2021 Celularity Garners IND Clearance for NK-Cell Therapy, Immunotherapy Combo Trial Nov 17, 2021 Imugene to Begin Phase II Trial of B-Cell Immunotherapy in HER2-Postive Gastric Cancer Oct 7, 2021 Precirix Begins Study of Precision Radiopharmaceutical in HER2-Positive Breast, Gastric Cancers Sep 29, 2021 UPenn Researcher Wins $250K Grant to Define CTNNA1-Related Gastric Cancer Risks Sep 17, 2021 CHMP Recommends BMS' Opdivo Plus Chemo for First-Line PD-L1-Positive Gastric Cancers Sep 17, 2021 In Brief This Week: Zai Lab, Roche, Realm IDx Sep 16, 2021 AstraZeneca, Daiichi Sankyo Begin New Gastric Cancer Enhertu Trial in China Load More Breaking News FDA Approves Taiho Oncology's Lytgobi for FGFR2-Rearranged Bile Duct Cancer Gladstone Institute Joins With Parker Institute on New Center to Study CRISPR-Based Cell Therapies Meliora Therapeutics Raises $11M in Seed Financing In Brief This Week:Â Verismo Therapeutics, Fore Biotherapeutics, Merck, Caris Life Sciences Tumor-Only Sequencing Found to Overestimate Mutational Burden in Non-European Patients Atara Biotherapeutics to Net $30M From Pierre Fabre for European Tab-Cel Approval
